TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsRegeneron says its COVID-19 antibody therapy showed promise in patients
The company is testing the therapy, a combination of two antibodies casirivimab and imdevimab, in hospitalized patients requiring low-flow oxygen.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. Sept.17. (Reuters/Brendan McDermid)
R
egeneron Pharmaceuticals said on Tuesday initial data from an ongoing study of its experimental antibody cocktail for use in some hospitalized COVID-19 patients show the therapy was sufficiently effective to warrant continuing the trial.
The company is testing the therapy, a combination of two antibodies casirivimab and imdevimab, in hospitalized patients requiring low-flow oxygen.
The drugmaker said in September the cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients.
Study participants included those who produced an effective immune response on their own (seropositive), and those whose immune response was not yet adequate (seronegative).
Seronegative patients treated with the antibody cocktail had a lower risk of death or needing mechanical ventilation, the company said.
Based on these results, the company said an ongoing late-stage study in hospitalized patients will continue.
The US Food and Drug Administration last month issued emergency use authorization for the antibody therapy for use in mild to moderate COVID-19 patients who are not currently hospitalized.
